FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2025年10月20日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 ...

Summary of Key Points Core Viewpoint - On October 17, 42 Hong Kong-listed companies conducted share buybacks, totaling 46.36 million shares and an aggregate amount of HKD 621 million [1][2]. Company-Specific Summaries - **Xiaomi Group-W**: - Repurchased 10.70 million shares for HKD 494 million, with a highest price of HKD 46.760 and a lowest price of HKD 45.900. The total buyback amount for the year reached HKD 1.537 billion [1][2]. - **Sihuan Pharmaceutical**: - Repurchased 15 million shares for HKD 21.76 million, with a highest price of HKD 1.470 and a lowest price of HKD 1.430. The total buyback amount for the year reached HKD 143.32 million [1][2]. - **Mengniu Dairy**: - Repurchased 1.20 million shares for HKD 16.97 million, with a highest price of HKD 14.250 and a lowest price of HKD 14.070. The total buyback amount for the year reached HKD 433.54 million [1][2]. - **AAC Technologies**: - Repurchased 300,000 shares for HKD 11.60 million, with a highest price of HKD 38.800 and a lowest price of HKD 38.480. The total buyback amount for the year reached HKD 84.64 million [1][2]. - **Vitasoy International**: - Repurchased 1.02 million shares for HKD 8.20 million, with a highest price of HKD 8.040 and a lowest price of HKD 8.020. The total buyback amount for the year reached HKD 27.54 million [1][2]. Overall Market Activity - The highest buyback amount on October 17 was from Xiaomi Group-W at HKD 494 million, followed by Sihuan Pharmaceutical at HKD 21.76 million. Other notable companies included Mengniu Dairy and AAC Technologies [1][2]. - In terms of share quantity, Sihuan Pharmaceutical led with 15 million shares repurchased, followed by Xiaomi Group-W with 10.70 million shares and Anton Oilfield Services with 4.49 million shares [1][2].

Core Viewpoint - Multiple companies in China conducted share buybacks on October 17, 2025, with Xiaomi Group-W leading in terms of buyback amount and quantity [1][2] Group 1: Buyback Details - Xiaomi Group-W (01810) repurchased 10.70 million shares for a total of 494 million yuan, with a year-to-date total of 27.30 million shares, representing 0.110% of its total share capital [2] - Four Seasons Pharmaceutical (00460) repurchased 15 million shares for 21.76 million yuan, with a year-to-date total of 59.60 million shares, representing 0.647% of its total share capital [2] - Mengniu Dairy (02319) repurchased 1.20 million shares for 16.97 million yuan, with a year-to-date total of 18.52 million shares, representing 0.473% of its total share capital [2] Group 2: Other Notable Buybacks - VITASOY International (00345) repurchased 1.02 million shares for 8.20 million yuan, with a year-to-date total of 566.60 million shares, representing 0.540% of its total share capital [2] - Zhongtong Express-W (02057) repurchased 445,000 shares for 8.41 million yuan, with a year-to-date total of 5.07 million shares, representing 0.630% of its total share capital [2] - Huazhong Media (00685) repurchased 500,000 shares for 50,000 yuan, with a year-to-date total of 225.60 million shares, representing 0.139% of its total share capital [2]

Summary of Key Points Core Viewpoint - 医渡科技 has been actively repurchasing its shares, indicating confidence in its market position and future prospects [1] Group 1: Share Buyback Activity - On October 17, 医渡科技 spent HKD 1.013 million to repurchase 181,000 shares [1] - This week, the company has conducted three buybacks totaling approximately 2.685 million shares, with a total expenditure exceeding HKD 15.6 million [1] - Since September 26, the company has executed five buybacks, amounting to around 3.373 million shares and nearly HKD 20 million in total [1] Group 2: Southbound Capital Inflows - On October 14, southbound funds net purchased HKD 34.7273 million worth of 医渡科技 shares, marking the highest net inflow since September 1, 2025 [1] - The net buying has continued for three consecutive days, with a cumulative net purchase of HKD 57.79 million [1] Group 3: Product Development and Market Support - Recently, the world's first topical treatment for proliferative superficial infantile hemangioma, Timolol Maleate Gel, has been approved for market release [1] - 医渡科技 provided critical market research and project analysis services that supported the drug's development and market entry [1]

Core Viewpoint - 医渡科技 announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1 - The company plans to repurchase 181,200 shares at a total cost of HKD 1.0131 million [1] - The buyback price per share ranges from HKD 5.56 to HKD 5.65 [1] - The buyback is scheduled for October 17, 2025, reflecting a strategic move to enhance shareholder value [1]

智通财经APP讯，医渡科技(02158)发布公告，于2025年10月17日，该公司斥资101.31万港元回购18.12万 股股份，每股回购价格为5.56-5.65港元。 ...

Core Viewpoint - The company, Yidu Tech (02158.HK), announced a share buyback on October 17, 2023, spending HKD 1.013 million to repurchase 181,000 shares at a price range of HKD 5.56 to 5.65 per share [1] Summary by Category - **Company Actions** - Yidu Tech executed a buyback of 181,000 shares at a total cost of HKD 1.013 million [1] - The repurchase price per share ranged from HKD 5.56 to 5.65 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2025年10月17日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 第一章節註釋： | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不包括庫存股 ...

Core Insights - The core viewpoint of the news is that Yidu Technology, a leading player in China's AI healthcare industry, has made significant progress across various business segments, including clinical research services, hospital AI construction, innovative drug development support, and health insurance operations, showcasing a strong trend of collaborative development among its diverse business lines. Group 1: Clinical Research Services - Yidu Technology successfully won the bid for the phase III clinical research project of recombinant human nerve growth factor (SMR001) eye drops for Shandong Yandu Biotechnology Co., with a total project amount of approximately RMB 55.82 million [2] - The company also secured a project for AI construction at Beijing Cancer Hospital, amounting to RMB 4.88 million, marking the first large model application project at a hospital level, setting a precedent for future large model business expansion [2] Group 2: Innovative Drug Development - In the innovative drug development support sector, the first innovative drug DF-006 developed by Drug Ranch has received approval from the China National Medical Products Administration to conduct phase 1b clinical trials in patients with chronic hepatitis B [3] - Yidu Technology played a crucial role as a service support provider for this project, leveraging its regulatory expertise and efficient project execution to facilitate the successful approval of the clinical trial application [3] Group 3: Health Insurance Operations - As the main operating platform for "Beijing Inclusive Health Insurance," Yidu Technology actively supported the 2025 Financial Education Promotion Week [4] - By the end of August 2025, the "Beijing Inclusive Health Insurance" had processed a total of 419,000 claims, with the highest single claim amount reaching RMB 761,100, and 89% of claims being processed quickly, effectively providing medical coverage for residents of Beijing [4] - The solid advancement of various business segments reflects Yidu Technology's professional capabilities and innovative vitality in the medical AI field, accelerating the synergy of its diverse business operations and laying a solid foundation for future development [4]

Summary of Key Points Core Viewpoint - A number of companies, including Xiaomi Group and Kuaishou, conducted share buybacks on October 14, 2025, with Xiaomi leading in terms of buyback amount and quantity [1]. Group 1: Buyback Details - Xiaomi Group-W (01810) repurchased 4 million shares for a total of 195 million, with a year-to-date total of 10.5954 million shares, representing 0.040% of its total share capital [2]. - Kuaishou-W (01024) repurchased 1.3146 million shares for 98.4067 million, with a year-to-date total of 3.4516 million shares, representing 0.081% of its total share capital [2]. - Shoucheng Holdings (00697) repurchased 16.05 million shares for 36.3578 million, with a year-to-date total of 90.146 million shares, representing 1.237% of its total share capital [2]. Group 2: Other Notable Buybacks - Vitasoy International (00345) repurchased 1.3980 million shares for 11.3964 million, with a year-to-date total of 4.25 million shares, representing 0.405% of its total share capital [2]. - IGG (00799) repurchased 150,000 shares for 6.145 million, with a year-to-date total of 17.809 million shares, representing 1.527% of its total share capital [3]. - China Hongqiao (01378) repurchased 300,000 shares for 7.594 million, with a year-to-date total of 154 million shares, representing 1.650% of its total share capital [2].